- Home
- CVKD vs MTVA Comparison
CVKD vs MTVA Comparison
Compare CVKD & MTVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVKD
- MTVA
- Stock Information
- Founded
- CVKD 2022
- MTVA 2014
- Country
- CVKD United States
- MTVA United States
- Employees
- CVKD N/A
- MTVA N/A
- Industry
- CVKD Medicinal Chemicals and Botanical Products
- MTVA
- Sector
- CVKD Health Care
- MTVA
- Exchange
- CVKD Nasdaq
- MTVA NYSE
- Market Cap
- CVKD 29.5M
- MTVA 14.3M
- IPO Year
- CVKD 2023
- MTVA N/A
- Fundamental
- Price
- CVKD $12.05
- MTVA $0.64
- Analyst Decision
- CVKD Strong Buy
- MTVA Strong Buy
- Analyst Count
- CVKD 1
- MTVA 2
- Target Price
- CVKD $32.00
- MTVA $7.50
- AVG Volume (30 Days)
- CVKD 30.9K
- MTVA 142.2K
- Earning Date
- CVKD 08-06-2025
- MTVA 08-13-2025
- Dividend Yield
- CVKD N/A
- MTVA N/A
- EPS Growth
- CVKD N/A
- MTVA N/A
- EPS
- CVKD N/A
- MTVA N/A
- Revenue
- CVKD N/A
- MTVA N/A
- Revenue This Year
- CVKD N/A
- MTVA N/A
- Revenue Next Year
- CVKD N/A
- MTVA N/A
- P/E Ratio
- CVKD N/A
- MTVA N/A
- Revenue Growth
- CVKD N/A
- MTVA N/A
- 52 Week Low
- CVKD $5.70
- MTVA $0.63
- 52 Week High
- CVKD $22.90
- MTVA $5.30
- Technical
- Relative Strength Index (RSI)
- CVKD 41.92
- MTVA N/A
- Support Level
- CVKD $10.02
- MTVA N/A
- Resistance Level
- CVKD $13.30
- MTVA N/A
- Average True Range (ATR)
- CVKD 1.04
- MTVA 0.00
- MACD
- CVKD -0.22
- MTVA 0.00
- Stochastic Oscillator
- CVKD 34.22
- MTVA 0.00
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.
About MTVA METAVIA INC
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for the treatment of obesity that is designed to be administered once weekly subcutaneously.